Australia's most trusted
source of pharma news
Thursday, 26 February 2026
Posted 26 February 2026 AM
BioMarin has voluntarily pulled Roctavian from all markets before the one-shot gene therapy for haemophilia A could even reach Australia.
In 2023, Roctavian made Clarivate’s 15-strong Drugs to Watch list, which names candidates set to either deliver annual sales of more than US$1 billion in the next five years or transform paradigms to meet unmet patient needs – the same year it was accepted for TGA review under orphan status.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.